Mitazalimab
Phase 3Monoclonal antibody
Mitazalimab is one of 97 small molecule programs targeting Biliary Tract Cancer. It is currently in Phase 3.
2
Indications
3
Total Trials
2
Active Trials
96
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
307 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Mitazalimab
UUniversity of Pennsylvania
Phase 3
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Active Comparator
ModernaPreclinical
Sulfonylureas
Eli LillyPreclinical
HS-20093
Jiangsu Hansoh Pharmaceutical Co., Ltd.Preclinical
Hyperpolarized 13c Pyruvate
UUniversity of Maryland, Baltimore
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Combination Therapy1 trial
MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)
Completed·—·Phase 1·NCT05650918·22 enrolled
Biliary Tract Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mitazalimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Pennsylvania